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Confirming Burnet’s early hypothesis, elimination of self-reactive T cells in the thymus was demonstrated in the
late 1980s, and an important question immediately arose about the nature of the self-peptides expressed in the thy-
mus.Many genes encoding neuroendocrine-related and tissue-restricted antigens (TRAs) are transcribed in thymic
epithelial cells (TECs). They are thenprocessed for presentation byproteins of themajor histocompatibility complex
(MHC) expressed by TECs and thymic dendritic cells. MHC presentation of self-peptides in the thymus programs
self-tolerance by two complementary mechanisms: (1) negative selection of self-reactive “forbidden” T cell clones
starting already in fetal life, and (2) generation of self-specific thymic regulatory T lymphocytes (tTreg cells), mainly
after birth. Many studies, including the discovery of the transcription factors autoimmune regulator (AIRE) and
fasciculation and elongation protein zeta family zinc finger (FEZF2), have shown that a defect in thymus central
self-tolerance is the earliest event promoting autoimmunity. AIRE and FEZF2 control the level of transcription
of many neuroendocrine self-peptides and TRAs in the thymic epithelium. Furthermore, AIRE and FEZF2 muta-
tions are associated with the development of autoimmunity in peripheral organs. The discovery of the intrathymic
presentation of self-peptides has revolutionized our knowledge of immunology and is opening novel avenues for
prevention/treatment of autoimmunity.
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Summary of thymus history
The word “thymus” first appeared in the manus-
cripts of Claudius Galen (129−around 216 A.D.)
and was described as an excrescence having some
morphological analogy with the leaf of the plant
Thymus cunila (savory or “sarriette” in French).
Galen thought that the thymus had no other func-
tion than providing protection between the sternum
and superior vena cava. Galen also observed that the
size of the thymus was larger in young animals and
decreased with aging.1,2
Over many centuries, the anatomy of the thy-
mus was the essential focus of the studies on this
organ until the Scottish embryologist John Beard
(1858−1924), a pioneer of today’s theory of can-
cer stem cells, wrote that he considered the thymus
to be the source of some white blood cells in the
body.3,4
In 1890, the German anatomist Wilhelm
Waldeyer (1836−1921) noticed that in elderly
people islets of normal thymic tissue could be
observed even after adipose involution of this
organ. Jan-August Hammar (Sweden, 1841−1946)
also showed that, although thymic development is
maximal at puberty, normal thymic tissue persists
until advanced age. He observed that animal cas-
tration before puberty prevents thymic involution
with age and that thymic hypoplasia is associated
with pregnancy, undernourishment, and some
infectious diseases. He showed that, conversely,
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thymic hyperplasia is associated with autoimmune
Graves’ thyroid disease, Addison’s adrenal insuffi-
ciency, myasthenia, and acromegaly.5 The thymus
was then seen just as another glandular component
of the endocrine system, and this assumption was
reinforced by Hans Selye’s observation of a severe
thymic atrophy in stressful conditions activating
the hypothalamic−pituitary−adrenal axis.6
The first immunological function of the thy-
mus was discovered when French-born Australian
immunologist Jacques F.A.P. Miller showed that
thymectomy performed in mice immediately after
birth rendered them highly susceptible to infec-
tions and provoked their premature death. He also
observed a marked lymphopenia in blood, spleen,
and lymph nodes of these mice. These animals were
also unable to reject a foreign skin graft, an essen-
tial hallmark of the immune response at that time.
Miller concluded that the thymus was the organ
responsible for the development of immunocompe-
tent cells that constitute a specific cell population,
thymus-dependent (T) lymphocytes.7,8 Despite the
rightness of Miller’s experiments and conclusions,
the British immunologist Sir Peter Medawar (the
1960 Nobel Prize), regarded as the father of trans-
plantation, still wrote in 1963: “We shall come to
regard the presence of lymphocytes in the thy-
mus as an evolutionary accident of no very great
significance.”9
In the perspective of hematopoietic growth fac-
tors identified at that time, Miller advanced the
hypothesis of one or several soluble thymic fac-
tors that would be responsible for driving T cell
differentiation.10 Innumerable studies worldwide
failed to demonstrate the existence of such thymus-
specific growth factor(s)/hormone(s) and it was
never possible to apply the endocrine model to
the communication between thymic epithelial cells
(TECs) and thymocytes (T cells). The demonstra-
tion of a crucial role of the thymus during fetal life,
as well as the absence of any pathogenicity resulting
from thymectomy a few days after birth, reinforced
the idea that the thymus was, if not a vestigial organ,
at least an organ that quickly becomes useless, this
being verified in human clinics: the DiGeorge con-
genital syndrome, which is the most common form
of genetic microdeletion, associates, together with
other defects, with the absence or hypoplasia of the
thymus and severe immunodeficiency. On the other
hand, children who have been thymectomized dur-
ing surgical correction of a congenital cardiac defect
do not suffer from any patent immune deficiency
further in life.
Immunological self-tolerance
Since the foundation of immunology at the end
of the 19th century, prediction of autotoxic-
ity/autoimmunity has been intimately associated
with the discovery of antitoxins/antibodies. As
soon as in 1900, Paul Ehrlich (1854−1915, the
1908 Nobel Prize) proposed the aphorism “horror
autotoxicus” to claim the impossibility that one
organism could be attacked under normal con-
ditions by its own cells in charge for its defenses.
Ehrlich thought then that either structures ormech-
anisms should exist to avoid autotoxicity, and this
should be of the highest importance for individual
health and species survival.11 In the continuation
of his revolutionary theory of clonal selection, the
Australian virologist and immunologist Sir Frank
Macfarlane Burnet (1899−1985), who shared the
1960 Nobel Prize with Medawar, introduced the
term tolerance to characterize one of the cardinal
properties of the adaptive immune system with
diversity and memory. In marked contrast with
Medawar’s statement, during a conference at the
University of London in 1962, Burnet prophesized:
“If, as I think, the thymus is the site where occurs
proliferation of lymphocytes in clones with precise
immunological functions, we have also to consider
another function: elimination or inhibition of
clones with reactivity to self.”
Afterward, the molecular mechanisms respon-
sible for the stochastic recombination of gene
segments encoding the variable domains of the
immunoglobulin B cell receptor for the antigen
(BCR)12 and T cell receptor (TCR) for the antigen
were elucidated.13–15 The fantastic lottery behind
the generation of diversity in the adaptive immune
system may produce more than 1030 cumulated
TCR and BCR combinations, the majority of which
are able to recognize self-antigens. In normal con-
ditions, however, the adaptive immune system does
not aggress self and, for a long time, immunol-
ogy was defined as the science of self−nonself dis-
crimination. Burnet was actually speaking about
immunology as the science of self and nonself
recognition. Indeed, without “training,” lympho-
cytes are not able to discriminate between self- and
nonself-peptides. In 1987 and 1988, the research
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groups of Douarin,16 Kappler and Marrack,17
MacDonald,18 and von Boehmer19 demonstrated
the validity of the theory of thymic clonal negative
selection proposed by Burnet many years before.
These independent studies clearly evidenced that
education to self and establishment of T cell self-
tolerance is imperative even before the acquisition of
T cell immunocompetence. Therefore, the thymus
is not only responsible for the generation of diver-
sity of the TCR repertoire, but is also primarily a
cemetery for early T cells expressing a TCR specific
for self-antigens that are presented to differentiat-
ing T cells by proteins of the major histocompatibil-
ity complex (MHC) expressed by TECs and thymic
dendritic cells (DCs).
In 1972, Richard Gershon (1932−1983) from
Yale identified immunosuppressive cells regulat-
ing competent lymphocytes.20 After his premature
death, his studies were pursued by Shimon Sak-
aguchi who, in a series of experiments, identi-
fied a novel key role for thymus-derived T cells
in the regulation of autoimmune responses.21–23
Indeed, mainly after birth, the thymus is the source
of a new population of tTreg cells that are able
to inhibit in the peripheral self-reactive T cells
having escaped negative selection in the thymus.
The Foxp3 transcription factor, through its expres-
sion in Treg cells, is essential for the prevention
of autoimmunity as shown in the human immune
dysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome, as well as in scurfy and
Foxp3−/− mice.24–26 The generation of tTreg cells
also depends on the presentation of self-antigens by
thymicMHCproteins. How the samemechanismof
MHC-mediated self-peptide presentation promotes
CD4+ fates that are so distinct during thymic T cell
differentiation (negative selection of self-reactive T
cells and generation of self-specific tTreg cells) is still
a matter of active exploration.27
A creative metaphor leading to a novel
paradigm: from neuropeptides to
neuroendocrine “self-peptides”
Following these seminal studies about the pow-
erful tolerogenic mechanisms occurring inside
the thymus, the real nature of self-peptides that
are presented by thymic MHC proteins was then
scrutinized. Previously, it was largely assumed that
proteins circulating in the blood were captured
somewhat “passively” in the thymus (by DCs and
macrophages, mainly) and then presented to dif-
ferentiating T lymphocytes during their transitory
residence in this organ. In 1978, immunoreactive
neurotensin (NT) and somatostatin were identified
in the chicken thymus epithelium,28 but these
observations were not followed further. In 1986,
synthesis of biologically active and immunore-
active oxytocin (OT), in equimolar content with
neurophysin, its binding protein derived from the
same precursor, was discovered in human thymus
extracts.29 In the thymus microenvironment, OT is
synthesized by TECs and not by thymocytes.30 Fol-
lowing the metaphor of the “nursing” of newborns
through OT galactagogue action, thymic “nurse”
cells (TNCs) were shown to be a cortical TEC
population synthesizing OT.31 Intrathymic of the
oxytocin gene (OXT) transcription coincides with
its expression in the hypothalamus.32 Furthermore,
functional neurohypophysial receptors (OTR and
V1b) are expressed by distinct thymic T cell subsets.
After binding to these receptors, OT—much more
than vasopressin (VP)—promotes phosphorylation
of T cell tyrosine kinases closely implicated in focal
adhesion, and this event could be implicated in
the formation of immunological synapses between
TECs and thymocytes.33 Neuropeptide Y (NPY),
neurokinin A (NKA),34 and insulin-like growth
factor-2 (IGF-2)35,36 were also found to be syn-
thesized in the thymic epithelium. The repertoire
of neuroendocrine-related precursors is organized
in such an economical way that one member per
family is predominantly expressed in TECs: OT for
the neurohypophysial family, NT for neuromedins,
NKA for tachykinins, and IGF-2 for the insulin
family.37,38 TECs were proposed to exhibit a more
“promiscuous” promoter use than other peripheral
tissues.39
Most importantly, in the thymus, the processing
of OT precursor does not lead to classic neu-
rosecretion as established a long time ago for the
hypothalamo−neurohypophysial axis. Thymic OT
is not located in classic secretory granules, but is
diffuse within TEC/TNC cytosol, in large clear
vacuoles, and around perimembranous space.40
Actually, OT precursor is processed for the pre-
sentation of OT peptide by thymic MHC class I
(MHC-I) molecules, and the neurophysin domain
of OT precursor is associated in this presenta-
tion through an MHC-I−neurophysin 55 kD
hybrid molecule.41 The biochemical mechanism
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underlying formation of this hybrid protein remains
to be specified but, nevertheless, these data suggest
an analogy of neurophysin function between, on
the one hand, the transport of the neurohormone
OT along hypothalamo−neurohypophysial neu-
rons to nerve endings in posterior pituitary and,
on the other hand, the intrathymic presentation to
pre-T cells of OT as a self-peptide of the neurohy-
pophysial family. The selective advantage of this
form of MHC-I presentation of OT is that it would
not be tightly restricted by MHC-I alleles and
would allow presentation of the OT cyclic struc-
ture. The behavior of thymic OT as a self-antigen
targeted to TEC plasma membrane was further
supported by the stimulation in the production by
cultured human TECs of interleukin-6 (IL-6) and
leukemia inhibitory factor through the immuno-
logical recognition of OT by specific OT-specific
monoclonal antibodies.42 This study suggests that
deadly self-recognition in the thymus could lead to
some cytokine release helpful for the survival and
development of thymocytes that do not recognize
self-peptides.
The hypothesis that a thymic neuropeptide
actually behaves as a self-peptide was further inves-
tigated with NT, a 13-amino acid linear neuropep-
tide. Intrathymic MHC-I presentation of NT was
demonstrated according to the biochemical rules of
MHC-I presentation as established by Hans-Georg
Rammensee’s laboratory in Tübingen.43 Inter-
estingly, the C-terminal sequence of NT includes
tyrosine, leucine, and isoleucine residues, which can
be used for anchorage to most ofMHC-I proteins.44
So, NT and NT-derived C-terminal fragments
could serve as natural ligands for a majority (if not
all) of MHC-I alleles, thus also without any tight
allelic restriction that is hardly conceivable for the
establishment of central immune self-tolerance to
a universal peptide. This hypothesis also concords
with the high degree of conservation of NT-related
C-terminal region during evolution. All these
studies allowed us to propose a theoretical model
that completely transposes at the molecular level
the function of the thymus in T cell development
and central self-tolerance. This was extensively
discussed in Refs. 37 and 38 (Fig. 1).
In the early 2000s, Bruno Kyewski, Jens Derbin-
ski, and Ludger Klein in Heidelberg further
proposed that promiscuous gene expression of
tissue-restricted antigens (TRAs) in the thymus was
a novel key to understand immune self-tolerance
and autoimmunity.45,46 Contrary to neuroen-
docrine self-peptides, TRAs do not behave as
accessory signals binding to cognate receptors dur-
ing T cell development. Also, while neuroendocrine
self-peptides are synthesized in all TECs, promis-
cuous gene expression of TRAs in the thymus is
a unique property of medullary TECs (mTECs)
subsets, and these genes are transiently transcribed
in clusters along chromosomes.47 After some
initial skepticism, the immunology field recog-
nized the importance of thymus-dependent central
self-tolerance.37,48,49 Kyewski’s group also showed
that thymic DCs are implicated in the presentation
of TRAs synthesized in mTECs indicating a unidi-
rectional transfer of self-peptides inside the thymic
cellular microenvironment.50 Patterns of promiscu-
ous expression of insulin and casein locus-related
genes also indicated that a stochastic mechanism
underlies their transcription in mTECs.51
The epigenetic regulation of promiscuous gene
expression in the thymus is currently under intense
investigation.52,53 Most probably, these studies
might explain in the future the hierarchy in the
expression of neuroendocrine self-peptides belong-
ing to the same family, the absence of parental
imprinting of IGF2 transcription in TECs,47 and
control of the immunological mirror of self in the
thymus.
A thymus defect as the earliest event
promoting autoimmunity
While the unique physiological function of the
thymus in programming central self-tolerance is
now well established, more and more experi-
mental observations point to a disturbance of
thymus-dependent tolerance as a key event in
the early development of organ-specific autoim-
mune diseases (Fig. 2). In 1973, Burnet already
predicted that “forbidden” T cell clones having
mutated from a state of self-tolerance to self-
reactivity could be a major event in the phys-
iopathology of autoimmunity.54 In the BioBreeding
(BB) rat, an animal model of type 1 diabetes melli-
tus (T1D), removal of the thymus at birth prevents
the appearance of autoimmune diabetes.55 Trans-
plantation of the thymus from diabetes-resistant
(DR) to diabetes-prone (DP) BB rats also inhibits
this spontaneous disease.56 In the nonobese dia-
betic (NOD) mouse, another animal model of T1D,
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Figure 1. The triple role of thymic neuroendocrine self-peptides in T cell differentiation. Following its transcription under AIRE
(or FEZF2) control in TEC, a neuroendocrine precursor X is processed according to two distinct pathways. On the one hand, it
is the source of a cryptocrine ligand X that is able to bind to a neuroendocrine cognate receptor expressed by T cells, to mobilize
secondmessengers (such as IP3), and to induce intracellular events (such as phosphorylation of the focal adhesion-related kinases
p125Fak and p130Cas for thymicOT). This constitutes a positive accessory signal during T cell development. On the other hand, the
same precursor X is also processed as the source of self-peptide(s) X that is presented by MHC proteins of TECs or after transfer
to thymic DCs. During fetal life, self-presentation induces negative selection of T cells that are randomly bearing a TCR specific
of this MHC−self-peptide X complex. Mainly after birth, self-presentation also promotes the generation of tTreg cells specific
to the same complex. The electron microscopy photograph is a generous gift from Martin Wiemann, now at the University of
Duisburg-Essen.
grafts of NOD thymuses to DR mouse strains
induce the occurrence of autoimmune diabetes in
recipients.57 Similarly, transplantation of embry-
onic NOD thymic epithelium to C57BL/6 athymic
mice induces in recipients autoimmune sialitis and
insulitis similar to those observed in adult female
NOD.58 Other authors also reported defects of cen-
tral tolerance and apoptosis of self-reactive T cells
in the NOD thymus.59,60
Several groups then addressed the fundamen-
tal question whether inhibition or a significant
decrease in intrathymic self-presentation could
result in a continuous release of “forbidden” self-
reactive T cells accumulating in the peripheral
repertoire, as well as to a decrease in the generation
of self-reactive tTreg cells. If this hypothesis was ver-
ified, it would be clear that a defect in thymic tolero-
genic function might determine early the develop-
ment of organ-specific autoimmune diseases. Our
laboratory investigated this question more particu-
larly for the pathogenesis of autoimmune insulin-
dependent T1D. Concerning the members of the
insulin gene family, IGF2 is highly expressed in
TECs in the cortex and medulla of the thymus from
different species. IGF1 transcripts are detected in all
TECs as well as in thymicmacrophages, while INS is
transitorily transcribed in rare subsets of mTECs.47
This hierarchical profile implicates that IGF-2 is
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• AIRE- and FEZF2 regulated transcription of neuroendocrine self-peptides and TRAs in TECs.
• Deletion of T cells with high affinity for MHC/self-peptide complexes.
• Selection of CD4+ CD25+ Foxp3+ tTreg, specific of self-peptides.
Thymus physiopathology
• Absence or decrease in expression/presentation of self-peptides in the thymus                                                           
(APECED/APS-1, Graves’ disease, Down syndrome, BB rat,…).
• Enrichment of T cell repertoire with “forbidden” self-reactive effector   T (Teff) cells.
• Decrease in selection of tTreg cells with specificity to self-peptides.
Bridge between self-reactive Teff cells and target auto-antigens
Role of environmental factors (viruses, anti-tumor immunotherapy, sex steroids, gut microbiota, 
diet, vitamin D deficiency, stress…)
Target antigens
Figure 2. Role of the thymus in programming central self-tolerance and in the development of autoimmunity. In normal con-
ditions, under the control of AIRE and FEZF2, TECs express numerous genes related to neuroendocrine families or encoding
TRAs.MHC presentation of these self-peptides induces T cell differentiation, negative selection of self-reactive T cells, and gener-
ation of tTreg cells with the same specificity. In pathological conditions, the decrease in intrathymic expression and presentation of
self-peptides leads to continuous generation in the blood of self-reactive “forbidden” T cells (Teff cells), as well as to a decrease in
the generation of self-specific tTreg cells. This is a condition, necessary but not sufficient, for the development of an autoimmune
response against target antigens. For the clinical manifestations of an autoimmune disease, the intervention of environmental
factors is also requested.
highly tolerated by the T cell system since T cell
tolerance is directly proportional to the intrathymic
concentration of self-peptides.61 Using fetal thymic
organ cultures, we also observed that T cell prolifer-
ation and differentiationwas severely inhibited after
the interference of IGF-mediated signaling between
TECs and thymocytes, an effect that was absent
after the blockade of proinsulin signaling.62 Igf2
transcription is detected in the thymus of BB-DR
rats but is absent in the thymus of ±85% of BB-
DP rats, in close coincidence with the incidence of
autoimmune diabetes in BB-DP rats.63 These data
may explain the BB-DP lymphopenia (including a
decrease in the frequency of rat Treg cells), as well
as defective programming of central tolerance to
insulin-secreting islet β cells.
A specific topography and hierarchy also exist
in the expression of the two mouse insulin genes,
Ins1 and Ins2. Ins2 transcription predominates in
murine mTECs, while Ins1 is mostly expressed in
islet β cells. These contrasted profiles explain why
insulitis and autoimmune diabetes are accelerated
in Ins2−/− NOD mice,64 whereas these processes
are significantly inhibited in Ins1−/− NOD mice.65
Levels of Ins2 transcription in the thymus also
modulate insulin-specific T cell tolerance.66 Inter-
estingly, thymic Ins2 transcription is independent
of glycemia and is markedly enhanced by an
anti-lymphotoxin-β monoclonal antibody.67 How-
ever, the insulin-specific transactivator Mafa also
promotes thymic Ins2 transcription and Mafa
inactivation was shown to reduce thymic Ins2
expression and to stimulate in parallel the gener-
ation of autoantibodies against anti-islet β cells.68
INS transcripts are quantified at a lower level in the
thymus of human fetuses with the genetic marker
insulin-dependent diabetes mellitus 2 (IDDM2) of
susceptibility to T1D.69,70
The identification of the autoimmune regu-
lator gene (AIRE), a member of the zinc-finger
gene family, played a major role in further evi-
dencing the central role played by a thymus
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dysfunction in the pathogenesis of organ-specific
autoimmunity.71 AIRE mutations determine a rare
recessive congenital syndrome called autoimmune
polyglandular syndrome type 1 or autoimmune
polyendocrinopathy-candidiasis-ectodermal dys-
trophy syndrome.72 Aire transcription is maximal
in mTECs, and Aire−/− mice develop several
autoimmune processes in parallel with a marked
decrease in the intrathymic expression of numer-
ous neuroendocrine self-peptides (including OT,
INS, IGF-2, and NPY) and many TRAs.73 Both
IDDM2 and AIRE transcription determine the
level of INS transcription in the human thymus.74
The development and differentiation of murine
Aire-expressing mTECs is regulated by RANK
signals from thymic CD4+CD3− lymphoid tissue
inducer cells.75 Interestingly, extrathymic Aire-
expressing cells were recently identified as distinct
bone marrow−derived tolerogenic cells that could
anergize in secondary lymphoid organs effector
self-reactive CD4+ T cells having escaped thymic
negative selection.76,77
More recently, it has been shown that the gene
Fezf2 encoding fasciculation and elongation pro-
tein zeta family zinc finger-2 protein also con-
trols intrathymic transcription of self-peptides, the
majority of which are not regulated by Aire. Fezf2
disruption is also associated with autoimmune pro-
cesses in the periphery.78 Noteworthy, Fezf2 is also
a transcription factor implicated in some devel-
opmental processes of the central nervous system
(CNS).
With regard to the most frequent autoim-
mune endocrine disease, all major thyroid-specific
autoantigens, such as thyroperoxydase, thyroglobu-
lin, and thyrotropin receptor (TSHR), are also tran-
scribed in human TECs in normal conditions.79–81
It was further shown that homozygotes for an SNP
allele predisposing to Graves’ disease have signifi-
cantly lower intrathymicTSHR transcripts than car-
riers of the protective allele.82
A defect in α-myosin expression in TECs exerts
a major role in the physiopathology of autoim-
mune myocarditis,83 and a defect in Aire-mediated
central tolerance to myelin protein zero promotes
the appearance of an autoimmune TH1 effec-
tor response toward peripheral nerves.84 There is
also large supportive evidence that thymic toler-
ance plays an essential role in CNS autoimmune
diseases.85
Coevolution of immune and
neuroendocrine systems
The innate immune system evolves in parallel with
the neuroendocrine system in all living species
without any sign of autotoxicity/autoimmunity
(Fig. 3). Toll-like receptors, which are major medi-
ators of innate immunity, do not react against nor-
mal or undamaged self. Primitive forms of immune
diversity are present in agnathans, mediated by
diverse variable lymphocyte receptors, with 4−12
leucine-rich repeat modules that were most proba-
bly assembled by some gene conversion process.86
About 450–500 million years ago, the emergence
of transposon-like recombination–activating genes
Rag1 and Rag2 in jawed fishes was responsible for
the appearance of a novel and highly complex sys-
tem of immune defenses, the adaptive immunity.
The subsequent development of the combinatorial
immune systemhas been sometimes regarded as the
immunological “Big Bang.” Because of its high risk
of autotoxicity inherent to its diversity, the emer-
gence of adaptive immunity exerted an evolution-
ary pressure so strong that, according to Ehrlich’s
prediction of horror autotoxicus, novel structures
and mechanisms appeared with the specific role
of orchestrating immune self-tolerance. The first
unique thymus also appeared in sharks and rays but
it was preceded by thymoid lymphoepithelial struc-
tures located in the gill baskets of lamprey larvae.87
These structures express the gene encoding fork-
head box N4 (Foxn4), the paralog of Foxn1, which
is responsible for the differentiation of the thymic
epithelium in most vertebrates. Thus, Foxn4/Foxn1
determined the emergence of the thymic epithe-
lium,which is an absolute requirement for T cell dif-
ferentiation and programming of central immune
self-tolerance.88
The hierarchy observed in the organization of the
thymic repertoire of neuroendocrine self-peptides
has also evolutive implications. Neuroendocrine
functions having been installed before adaptive
immunity, they had to be protected against autoim-
munity. OT is implicated at different steps of the
reproductive process and is therefore fundamental
for the preservation of animal and human species.
Because of its predominance in the thymus, OT
is much more tolerated than VP, its neurohy-
pophysial homolog, which mainly regulates water
homeostasis and vascular pressure. This lower
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Figure 3. Integrated evolution of the immune and neuroendocrine systems. Neuroendocrine precursors did not evolve exten-
sively except by gene duplication and differential RNA splicing. Throughout evolution, the neuroendocrine and innate immune
system have evolved in parallel, and still coexist in all living species without any aggression of the innate immune system toward
neuroendocrine glands. A high risk of inherent autoimmunity toward neuroendocrine tissues resulted from the appearance of
recombination-activating genesRAG1 and RAG2, and RAG-dependent adaptive immunity in jawed cartilaginous fishes some 450
million years ago. Preceded by ancestor paralog Foxn4-expressing thymoids in gill baskets of lamprey larvae, the first unique thy-
mus (with Foxn1-expressing TECs) also emerged in jawed vertebrates. The intrathymic presentation of dominant neuroendocrine
self-peptides (arrows) may be viewed a posteriori as a very efficient and economical way to instruct the adaptive T cell system in
recognizing and tolerizing neuroendocrine families already during thymus-dependent T cell differentiation in fetal life. VCBP,
variable region-containing chitin-binding protein; VLR, variable lymphocyte receptor.
immunological tolerance of VP may explain why
rare cases of autoimmune central diabetes insipidus
have been repeatedly observed.89
In the insulin family, insulin is the primary
T1D autoantigen and no autoimmunity has been
reported against IGF-2, which is fundamental
for fetal growth and development. Nevertheless,
because of their homology, thymic neuroendocrine
self-peptides program immune cross-tolerance to
their whole family, and tolerance of insulin is indeed
decreased in Igf2−/− mice.90
Conceptual translation: from immunogenic
to tolerogenic vaccines
Until now, the development of anti-infective vac-
cines was essentially based on immunogenic and
memory properties of the adaptive immune system.
Future vaccines against autoimmune diseases could
be developed on the basis of the initial property
of self-tolerance programmed for this system and
recent knowledge about the potent tolerogenic
properties of the thymus, which have not been
exploited until now. As reported above, although
Ins2 is expressed at very low levels in rare mTEC
subsets, proinsulin per se does not exert any tolero-
genic properties that could be used to reprogram
immunological tolerance toward islet β cells. With
the exception of only two studies (that were not
confirmed until now),91,92 all the clinical trials
based on insulin failed to protect the residual β cell
mass from the diabetogenic autoimmune response.
At the opposite, the potent immunogenic proper-
ties of insulin were repeatedly evidenced,93,94 and
insulin immunogenicity could actually be linked
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Figure 4. Classical vaccination and the concept of “reverse” self-vaccination. Classical vaccination essentially relies on an
immunogenic response (naive T cell activation and induction of memory immune cells) elicited by administration of antigen(s)
representative of pathogens. T1D pathogenesis also relies on an immunogenic response targeting several T1D antigens, such as
insulin as the primary T1D autoantigen (X). The novel type of “reverse” self-vaccination proposes to use thymus self-peptides
for promoting a tolerogenic response (deletion of self-reactive T cells and generation of self-reactive Treg cells). For T1D preven-
tion and cure, the corresponding thymus self-peptide is IGF-2 (X′). Noteworthy, insulin is actually an “altered self” peptide of
IGF-2.101−103
to the very low level of INS transcription in mTEC
subsets. The risk of hypersensitivity or anaphylaxis
following administration of an autoantigen was also
reported.95
IGF-2 could provide a more efficient basis than
insulin for developing a specific “reverse/tolero-
genic self-vaccination”96 (Fig. 4) based on the fol-
lowing data:
 Igf2 is a dominant member of the insulin fam-
ily expressed in the thymus.35
 Igf2 transcription is defective in the thymus of
BB-DP rats.63
 IGF-2 B11−25 and insulin B9−23 (InsB9−23)
compete for binding to DQ2 andDQ8 (collab-
oration with K. Wücherpfennig, unpublished
data), the MHC-II alleles conferring the high-
est genetic susceptibility to T1D.
 Contrary to InsB9−23, IGF-2 B11−25 presen-
tation by peripheral blood mononuclear cells
isolated from DQ8+ diabetic patients induces
a tolerogenic cytokine profile with marked
IL-10 induction.97
 IGF-2 mediates significant cross-tolerance to
insulin.90
 Infection of a murine TEC line with the dia-
betogenic coxsackievirus B4-E2 inhibits Igf2
transcription and IGF-2 production.98
 IGF-2 induces the activation of Treg and Breg
cells.99,100
This promising concept of reverse tolerogenic
self-vaccination is under current development with
the active support of Wallonia DGO6 Win2Wal
THYDIA Project.
Conclusion
Far from being a useless “vestigial” organ, numer-
ous studies performed worldwide have defini-
tively demonstrated that the thymus is crucial for
ensuring the global homeostasis of the adaptive
immune system and is unique in programming
central immune self-tolerance. Presentation of self-
peptides in the thymus is the basic mechanism that
underlies T cell differentiation, negative selection of
self-reactive T cell clones, and generation of tTreg
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cells. There is no doubt that thymus-based novel
strategies could alleviate in the future the weight of
somany known and still unknown autoimmunedis-
eases that remain the heavy tribute, mainly paid by
mankind, for the performance and extreme diver-
sity of its highly complex adaptive immunity.
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